Saranya AuparakkitanonSoebsakul ChapoomramKannika KuahaThamrong ChirachariyavejPrapon WilairatFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityMahidol UniversityKhon Kaen University2018-08-202018-08-202006-06-01Antimicrobial Agents and Chemotherapy. Vol.50, No.6 (2006), 2197-2200006648042-s2.0-33744466289https://repository.li.mahidol.ac.th/handle/123456789/23738Pyronaridine, 2-methoxy-7-chloro-10[3′,5′-bis(pyrrolidinyl-1- methyl-)4′hydroxyphenyl]aminobenzyl-(b)-1,5-naphthyridine, a new Mannich base schizontocide originally developed in China and structurally related to the aminoacridine drug quinacrine, is currently undergoing clinical testing. We now show that pyronaridine targets hematin, as demonstrated by its ability to inhibit in vitro β-hematin formation (at a concentration equal to that of chloroquine), to form a complex with hematin with a stoichiometry of 1:2, to enhance hematin-induced red blood cell lysis (but at 1/100 of the chloroquine concentration), and to inhibit glutathione-dependent degradation of hematin. Our observations that pyronaridine exerted this mechanism of action in situ, based on growth studies of Plasmodium falciparum K1 in culture showing antagonism of pyronaridine in combination with antimalarials (chloroquine, mefloquine, and quinine) that inhibit β-hematin formation, were equivocal. Copyright © 2006, American Society for Microbiology. All Rights Reserved.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1128/AAC.00119-06